Precision Medicine Using Pharmacogenomic Panel-Testing

Advances in Molecular Pathology, vol. 3, pp. 131–142

Abstract

Pharmacogenomics Panel-testing Implementation Adverse drug reactions KEY POINTSLogistics and cost-effectiveness of pharmacogenomics (PGx)-guided prescribing may be optimized when delivered in a preemptive panel approach.Barriers impeding implementation of a preemptive PGx-panel approach include the lack of evidence of (cost-) effectiveness, the undetermined optimal target population and timing for delivering PGx, and the lack of tools supporting implementation.Developments in sequencing and artificial intelligence will further improve the predictive utility of genetic variation to predict drug response.

Authors 3

1. Cathelijne H. van der Wouden Aachen Department of Clinical Pharmacy and Toxicology

   Leiden University Medical Center

   Affiliation as printed

   Department of Clinical Pharmacy & Toxicology, Leiden University Medical Center, Albinusdreef 2, Leiden 2333ZA, The Netherlands

   Leiden Network for Personalised Therapeutics, Leiden, The Netherlands

2. Henk‐Jan Guchelaar Aachen Department of Clinical Pharmacy and Toxicology

   Leiden University Medical Center

   Affiliation as printed

   Department of Clinical Pharmacy & Toxicology, Leiden University Medical Center, Albinusdreef 2, Leiden 2333ZA, The Netherlands

   Leiden Network for Personalised Therapeutics, Leiden, The Netherlands

3. Jesse Joachim Swen corresponding Aachen Department of Clinical Pharmacy and Toxicology

   Leiden University Medical Center

   Affiliation as printed

   Department of Clinical Pharmacy & Toxicology, Leiden University Medical Center, Albinusdreef 2, Leiden 2333ZA, The Netherlands

   Leiden Network for Personalised Therapeutics, Leiden, The Netherlands